-- Clovis Oncology (NASDAQ: CLVS) reported a fourth-quarter 2019 loss of $1.81 per share versus a loss of $1.71 per share expected.
Clovis Oncology Inc
-(CLVS)
XNAS:CLVS
Tesaro shares spike on buyout news, trading halted
Shares of Tesaro (TSRO), an oncology-focused biopharma company, skyrocketed after the news that it has been working with advisors for a possible sale.